<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27885491</article-id><article-id pub-id-type="pmc">5216084</article-id><article-id pub-id-type="publisher-id">442</article-id><article-id pub-id-type="doi">10.1007/s12325-016-0442-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: <italic>nab</italic>-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tehfe</surname><given-names>Mustapha</given-names></name><address><email>mustapha.tehfe.chum@ssss.gouv.qc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dowden</surname><given-names>Scot</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kennecke</surname><given-names>Hagen</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>El-Maraghi</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lesperance</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Couture</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Letourneau</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Romano</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label>Centre hospitalier de l&#x02019;universit&#x000e9; de Montr&#x000e9;al (CHUM), Montreal, QC Canada </aff><aff id="Aff2"><label>2</label>Tom Baker Cancer Centre, Calgary, AB Canada </aff><aff id="Aff3"><label>3</label>British Columbia Cancer Agency, Vancouver, BC Canada </aff><aff id="Aff4"><label>4</label>Royal Victoria Regional Health Centre, Barrie, ON Canada </aff><aff id="Aff5"><label>5</label>H&#x000f4;pital du Sacr&#x000e9;-Coeur de Montreal, Montreal, QC Canada </aff><aff id="Aff6"><label>6</label>Centre hospitalier universitaire de Qu&#x000e9;bec (CHUQ), H&#x000f4;tel-Dieu de Quebec, CHUM, Montreal, QC Canada </aff><aff id="Aff7"><label>7</label>Celgene Corporation, Summit, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>34</volume><issue>1</issue><fpage>277</fpage><lpage>279</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d29e91" ext-link-type="doi" xlink:href="10.1007/s12325-016-0327-4"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Adv Ther (2016) 33:747&#x02013;759 DOI 10.1007/s12325-016-0327-4</title><p>The authors would like to correct the errors in Table&#x000a0;1 and text in the published article. The correct table and the text should read as below.</p><p>In Table&#x000a0;1, the numbers for the intent-to-treat population for biliary stent and previous Whipple procedure were erroneously switched. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> should appear as below.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variable</th><th align="left" colspan="2">Patients in Canada</th><th align="left" rowspan="2">ITT population [9] (<italic>N</italic>&#x000a0;=&#x000a0;861)</th></tr><tr><th align="left">
<italic>nab</italic>-P&#x000a0;+&#x000a0;Gem (<italic>n</italic>&#x000a0;=&#x000a0;33)</th><th align="left">Gem (<italic>n</italic>&#x000a0;=&#x000a0;30)</th></tr></thead><tbody><tr><td align="left">Age, median (range), years</td><td align="left">61.0 (34&#x02013;77)</td><td align="left">61.5 (49&#x02013;72)</td><td align="left">63.0 (27&#x02013;88)</td></tr><tr><td align="left" colspan="4">Sex, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left">12 (36)</td><td align="left">9 (30)</td><td align="left">359 (42)</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">21 (64)</td><td align="left">21 (70)</td><td align="left">502 (58)</td></tr><tr><td align="left" colspan="4">KPS, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;100</td><td align="left">2 (6)</td><td align="left">3 (10)</td><td align="left">138 (16)<sup>a</sup>
</td></tr><tr><td align="left">&#x000a0;90</td><td align="left">18 (55)</td><td align="left">14 (47)</td><td align="left">378 (44)<sup>a</sup>
</td></tr><tr><td align="left">&#x000a0;80</td><td align="left">9 (27)</td><td align="left">12 (40)</td><td align="left">277 (32)<sup>a</sup>
</td></tr><tr><td align="left">&#x000a0;70</td><td align="left">4 (12)</td><td align="left">1 (3)</td><td align="left">63 (7)<sup>a</sup>
</td></tr><tr><td align="left">&#x000a0;60</td><td align="left">0</td><td align="left">0</td><td align="left">2 (&#x0003c;1)<sup>a</sup>
</td></tr><tr><td align="left" colspan="4">Number of metastatic sites, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">4 (12)</td><td align="left">1 (3)</td><td align="left">54 (6)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">11 (33)</td><td align="left">11 (37)</td><td align="left">408 (47)</td></tr><tr><td align="left">&#x000a0;&#x02265;3</td><td align="left">18 (55)</td><td align="left">18 (60)</td><td align="left">399 (46)</td></tr><tr><td align="left" colspan="4">Sites of metastases, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Liver</td><td align="left">27 (82)</td><td align="left">25 (83)</td><td align="left">725 (84)</td></tr><tr><td align="left">&#x000a0;Lung</td><td align="left">14 (42)</td><td align="left">18 (60)</td><td align="left">337 (39)</td></tr><tr><td align="left">&#x000a0;Peritoneum</td><td align="left">2 (6)</td><td align="left">1 (3)</td><td align="left">29 (3)</td></tr><tr><td align="left" colspan="4">Pancreatic tumor location, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Head</td><td align="left">18 (55)</td><td align="left">9 (30)</td><td align="left">371 (43)</td></tr><tr><td align="left">&#x000a0;Body</td><td align="left">11 (33)</td><td align="left">11 (37)</td><td align="left">268 (31)</td></tr><tr><td align="left">&#x000a0;Tail</td><td align="left">4 (12)</td><td align="left">10 (33)</td><td align="left">215 (25)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">0</td><td align="left">0</td><td align="left">7 (1)</td></tr><tr><td align="left" colspan="4">CA 19-9, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Normal</td><td align="left">3 (9)</td><td align="left">3 (10)</td><td align="left">116 (15)<sup>b</sup>
</td></tr><tr><td align="left">&#x000a0;&#x0003e;ULN and &#x0003c;59&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="left">11 (33)</td><td align="left">11 (37)</td><td align="left">242 (32)<sup>b</sup>
</td></tr><tr><td align="left">&#x000a0;&#x02265;59&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="left">16 (48)</td><td align="left">11 (37)</td><td align="left">392 (52)<sup>b</sup>
</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">3 (9)</td><td align="left">5 (17)</td><td align="left">111 (13)<sup>c</sup>
</td></tr><tr><td align="left">Biliary stent, <italic>n</italic> (%)</td><td align="left">11 (33)</td><td align="left">8 (27)</td><td align="left">148 (17)</td></tr><tr><td align="left">Previous Whipple procedure, <italic>n</italic> (%)</td><td align="left">3 (9)</td><td align="left">2 (7)</td><td align="left">62 (7)</td></tr></tbody></table><table-wrap-foot><p>
<italic>CA 19</italic>-<italic>9</italic> carbohydrate antigen 19-9, <italic>Gem</italic> gemcitabine, <italic>ITT</italic> intent-to-treat, <italic>KPS</italic> Karnofsky performance status, <italic>nab</italic>-<italic>P</italic> nab-paclitaxel, <italic>ULN</italic> upper limit of normal</p><p>
<sup>a</sup>Total evaluable patients&#x000a0;=&#x000a0;858</p><p>
<sup>b</sup>Total evaluable patients&#x000a0;=&#x000a0;750</p><p>
<sup>c</sup>This value was not reported in Ref. [9]</p></table-wrap-foot></table-wrap>
</p><p>The corresponding text for Table&#x000a0;1 under the Baseline Characteristics heading in the Results section should read, &#x0201c;Fewer patients in the Canadian cohort had a KPS of 100 than in the ITT population,&#x0201d; i.e., removing &#x0201c;or previous Whipple procedure&#x0201d; from the original sentence which read &#x0201c;Fewer patients in the Canadian cohort had a KPS of 100 or previous Whipple procedure than in the ITT population.&#x0201d;</p><p>Under the Statistical Analyses section, the second-to-last sentence reads &#x0201c;A nonstratified log-rank test was PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.&#x0201d; It should read &#x0201c;A stratified log-rank test was used to compare PFS between the treatment arms, and the HR and two-sided 95% CIs were estimated by a Cox proportional hazards model.&#x0201d;</p><p>In the Discussion (last paragraph beginning at the bottom of page 756), the sentence reads, &#x0201c;Health Canada has approved <italic>nab</italic>-P&#x000a0;+&#x000a0;Gem and FOLFIRINOX for the treatment of patients with MPC based on the phase III MPACT and PRODIGE trials (ClinicalTrials.gov identifier, NCT00112658), respectively, in which <italic>nab</italic>-P&#x000a0;+&#x000a0;Gem and FOLFIRINOX demonstrated superior efficacy vs. Gem alone [4, 9, 20].&#x0201d; It should read, &#x0201c;Based on the results of the phase III MPACT and PRODIGE trials (ClinicalTrials.gov identifier, NCT00112658), both the <italic>nab</italic>-P&#x000a0;+&#x000a0;Gem and FOLFIRINOX regimens are accessible in Canada; however, Health Canada only reviewed and approved <italic>nab</italic>-P&#x000a0;+&#x000a0;Gem for the first-line treatment of MPC [4, 7, 9, 20].&#x0201d;
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s12325-016-0327-4.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></ack></back></article>